Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.


To cite this version:

Binu Porath, Vladimir G Gainullin, Emilie Cornec-Le Gall, Elizabeth K Dillinger, Christina M Heyer, et al.. Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.. American Journal of Human Genetics, Elsevier (Cell Press), 2016, 98 (6), pp.1193-1207. <10.1016/j.ajhg.2016.05.004>. <hal-01328055>
Mutations to *GANAB*, encoding the glucosidase IIα subunit, cause autosomal dominant polycystic kidney and liver disease

Binu Porath¹, Vladimir G Gainullin¹, Emilie Cornec-Le Gall¹, Elizabeth K Dillinger⁴, Christina M Heyer¹, Katharina Hopp¹, Marie E Edwards¹, Charles D Madsen¹, Sarah R Mauritz¹, Carly J Banks¹, Saurabh Baheti⁶, Bharathi Reddy⁷, Jose Ignacio Herrero⁸, Jesus M Banales¹¹, Marie C Hogan¹, Vellbor Tasic¹², Terry J Watnick¹³, Arlene B Chapman⁷, Cécile Vigneau¹⁴, Frédéric Lavainne¹⁵, Marie-Pierre Audrézet², Claude Ferec², Yannick Le Meur³, Vicente E Torres¹, the Genkyst, HALT PKD and CRISP studies and Peter C Harris¹,⁴

¹Division of Nephrology and Hypertension, ⁴Department of Biochemistry and Molecular Biology, and ⁶Division of Biostatistics and Informatics, Mayo Clinic, Rochester, MN, 55905, USA, ²Department of Molecular Genetics, INSERM 1078, Brest, Brittany, 29200, France ³Department of Nephrology, University Hospital, Brest, Brittany, 29200, France. ⁵Division of Renal Diseases and Hypertension, University of Colorado Denver, Aurora, CO, 80202, USA, ⁷Section of Nephrology, University of Chicago, Chicago, IL, 60637, USA, ⁸Liver Unit, Clinica Universidad de Navarra, Pamplona, Navarra, 31009, Spain, ⁹Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), Madrid, 28029, Spain. ¹⁰Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Navarre, 31008, Spain. ¹¹Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, UPV/EHU, CIBERehd, Ikerbasque, San Sebastian, 20014, Spain, ¹²Department of Pediatric Nephrology, University Children’s Hospital, Skopje, 1010, Macedonia, ¹³Division of Nephrology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA, ¹⁴Department of Nephrology, University Hospital, Rennes, Bretagne, 35000, France, ¹⁵Department of Nephrology, University Hospital, Nantes, Pays De La Loire, 44000, France.

#These authors contributed equally to the study

*Correspondence should be addressed to P.C.H. (harris.peter@mayo.edu)
ABSTRACT
Autosomal dominant polycystic kidney disease (ADPKD) is a common, progressive, adult onset disease that is an important cause of end stage renal disease (ESRD), requiring transplantation or dialysis. Mutations to PKD1 or PKD2 (~85% and ~15% of resolved cases, respectively) are the known causes of ADPKD. Extrarenal manifestations include an increased level of intracranial aneurysms (ICA) and polycystic liver disease (PLD), which can be severe and associated with significant morbidity. Autosomal dominant PLD (ADPLD) with no/very few renal cysts is a separate disorder caused by PRKCSH, SEC63 or LRP5 mutations. After screening, 7-10% of ADPKD and ~50% of ADPLD families were genetically unresolved (GUR), suggesting further genetic heterogeneity of both disorders. Whole exome sequencing of six GUR ADPKD families identified one with a missense mutation to GANAB, encoding the glucosidase II, α subunit (GIIα). Since PRKCSH encodes the GII β subunit, GANAB was a strong ADPKD/ADPLD disease candidate. Sanger screening of 321 additional GUR families identified eight further likely mutations (six truncating), with a total of 20 affected individuals identified in seven ADPKD-like and two ADPLD-like families. The phenotype was mild PKD and variable, including severe, PLD. Analysis of GANAB null cells showed an absolute requirement of GIIα for maturation and surface/ciliary localization of the ADPKD proteins (PC1 and PC2), with reduced mature PC1 seen in GANAB<sup>−/−</sup> cells. PC1 surface localization in GANAB<sup>−/−</sup> cells was rescued by wildtype but not mutant GIIα. Overall we show that GANAB mutations cause ADPKD/ADPLD, with the cystogenesis likely driven by PC1 maturation defects.
INTRODUCTION

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited disorders, ~1/1000 individuals affected worldwide, that is characterized by progressive kidney cyst development and expansion\(^1\)\(^2\). In ~50% of cases, ADPKD results in end stage kidney disease (ESRD), with 4-10% of ESRD worldwide due to ADPKD\(^3\). ADPKD is caused by mutations to \(PKD1\) [MIM: 601313] or \(PKD2\) [MIM: 173910] (~85% and ~15% of mutation resolved families, respectively)\(^4\)-\(^7\). Genotype/phenotype studies indicate an average age at ESRD of 55.6y associated with truncating \(PKD1\) mutations, compared to 67.9y for \(PKD1\) non-truncating and 79.7y for PKD2 [MIM: 613095]\(^8\). An earlier decline in renal function (measured by estimated glomerular filtration rate; eGFR) and larger kidneys (height adjusted, MRI determined total kidney volume; hTKV) are also associated with PKD1 [MIM: 173900]\(^6\)-\(^9\). The PKD1 and PKD2 proteins, polycystin-1 (PC1) and PC2, respectively, are membrane glycoproteins, with the primary cilium a likely functional site\(^10\). PC1 is cleaved at the GPS site and this cleavage is essential for function\(^11\)-\(^12\). PC1 consists of two glycoforms of the N- and C-terminal GPS cleaved products – mature, Endoglycosidase H (EndoH) resistant (NTR/CTR) and immature, EndoH sensitive (NTS/CTS)\(^13\)-\(^15\). The level of the mature glycoforms is associated with disease severity, and complexing with PC2 is critical for PC1 maturation and surface/ciliary localization\(^13\)-\(^16\)-\(^17\).

In a number of comprehensive studies of the genes mutated in ADPKD, 7-10% of families are genetically unresolved (GUR)\(^6\)-\(^8\)-\(^18\). The typical finding of mild kidney disease in GUR cases\(^6\), suggests that few such families are explained by missed, fully penetrant mutations at the complex, segmentally duplicated, \(PKD1\) locus\(^4\)-\(^19\). However, hypomorphic mutations at the existing loci, including due to mosaicism\(^20\)-\(^21\), phenocopies associated with autosomal dominant tubulointerstitial kidney disease (ADTKD) loci\(^22\)-\(^23\) and phenotypic and screening mistakes likely
explain some unlinked/GUR families\textsuperscript{24}. Nevertheless, additional genetic heterogeneity seems possible.

Subjects affected by ADPKD have a \textasciitilde5x higher risk of developing intracranial aneurysms (ICA)\textsuperscript{25}. However, polycystic liver disease (PLD) is the most frequent extra-renal complication in ADPKD, with a proportion of mainly females developing severe PLD, requiring surgical intervention\textsuperscript{26; 27}. Unlike PKD severity, severe PLD is not associated with a particular genic or \textit{PKD1} allelic type\textsuperscript{26}. Isolated, autosomal dominant PLD (ADPLD [MIM: 174050]) is a separate inherited disorder where severe PLD can also occur, but renal cysts are absent/very rare\textsuperscript{28}. ADPLD is caused by mutations to \textit{PRKCSH} [MIM: 177060], \textit{SEC63} [MIM: 608648] or \textit{LRP5}\textsuperscript{29-32}. \textit{PRKCSH} encodes the glucosidase II, \(\beta\) subunit (GII\(\beta\) \textsuperscript{33; 34}, with GII being an ER-resident enzyme that catalyzes hydrolysis of the middle and innermost glucose residues on peptide-bound oligosaccharide and triggers quality control assessment of glycoprotein folding through the calnexin/calreticulin cycle\textsuperscript{35-40}. The SEC63 protein facilitates the translocation of secreted or membrane proteins across the endoplasmic reticulum (ER) membrane\textsuperscript{41-44}. Induced loss of \textit{Prkcs} or \textit{Sec63} in mouse kidneys results in PKD, with an interactive network with PC1 and PC2 proposed, with PC1 as the rate-limiting component\textsuperscript{14}. This suggests that \textit{PRKCSH} mutation may act through PC1 depletion, although PC2 reduction has also been noted with \textit{Prkcs} depletion/loss\textsuperscript{45; 46}. There is strong evidence of further genetic heterogeneity in ADPLD, with only \textasciitilde50\% of affected individuals explained by the known genes mutated in this disease\textsuperscript{28; 47}.

In this study we have employed global and focused screening of GUR ADPKD/ADPLD families to identify a gene mutated in ADPKD/ADPLD. Characterization of cells null for this gene links the pathogenesis to the maturation and localization of PC1 and PC2.

**SUBJECTS AND METHODS**
Sample and data collection and clinical analysis

The relevant institutional review boards and ethics committees approved all studies, and participants gave informed consent. Blood samples for DNA isolation samples were collected from the proband and all available family members and isolated by standard methods in the Mayo Biospecimens Accessioning and Processing Core, or the Genkyst study. Clinical and imaging data was obtained by review of clinical records. TKV and TLV was measured from clinical MR and CT images at the Mayo Translational PKD Center employing the stereology method with the Analyze software or a semi-automated approach, and adjusted for height (htTKV or htTLV). Enlarged kidneys or livers were defined as the mean +2SD of normal htTKV or htTLV adjusted for average height. Kidney function was calculated from clinical serum creatinine measurements using the CKD-EPI formula in adults and the Schwarz formula in the pediatric case and expressed as ml/min/1.73m². Age at onset of high blood pressure was defined as when the affected individual started antihypertensive medication.

Whole exome sequencing (WES) and bioinformatics analysis

Families were defined GUR when no mutations were detected from Sanger sequencing and MLPA analysis of the PKD1 and PKD2 genes. In addition, the Genkyst cohort, including families PK20016 and PK20017, and P1174, were screened for HNF1B [MIM:189907] mutations, and families with a possible ADPLD diagnosis, including P1073, M472 and M656, were screened for PRKCSH and SEC63 mutations.

Total genomic DNA was quantified using a Qubit 2.0 fluorometer (dsDNA BR assay kit) and quality checked with a NanoDrop. Subsequently, 250ng or 1μg of DNA was sheared by sonication (Covaris E210, 150-200bp), purified by AMPure XP beads (Agencourt), with shearing efficiency checked on a Agilent Bioanalyzer 2100 (DNA1000 assay). Whole exome capture and Illumina library preparation was performed using the Agilent SureSelectXT Human All Exon
V5+UTRs kit on an Agilent Bravo workstation. The enriched library was sequenced with 101bp paired-end reads on an Illumina HiSeq2000 in the Mayo Medical Genomics Facility. On average 3-4 exomes per lane were multiplexed. Genome_GPS v3.0.1 (Mayo Bioinformatics Core) was employed as a comprehensive secondary analysis pipeline for variant calling. In short, FASTQ files were aligned to the hg19 reference genome using Novoalign (VN:V2.08.01) with the following options: -hdrhd off -v 120 -c 4 -i PE 425,80 -x 5 -r Random, and realignment and recalibration performed using GATK (VN:3.3-0) best practices Version 3 for each family separately. Overall, 75.6% of mapped reads aligned to the captured region, and 98.9% of the captured region was covered at 10x read depth. Multi-sample variant calling was performed with the GATK (VN: 3.3-0) Haplotype Caller and variants filtered using the Variant Quality Score Recalibrator (VQSR) for both SNVs and InDels. Variant mining was performed employing Golden Helix SNP and Variation Suite v8 (SVS, Golden Helix, Inc). All families were analyzed independently with the following filtering procedure: (1) quality filter of read depth (≥10X) and genotype quality (≥20), (2) selection according to autosomal dominant sample genotype pattern, (3) removal of ExAC Browser variants with a minor allele frequency (MAF) of >0.1%, and (4) characterization and removal of coding and non-coding SNVs within 14bp of the splice site and/or predicted to be neutral by one or more of six dbNSFP tools (tools selected as filter criteria were: SIFT, Polyphen2 HVAR, Mutation Taster, Mutation Assessor, FATHMM, and FATHMM MKL) and dbscSNV (removed SNVs with Ada and RF scores <0.6). A list of variants that resulted after the SVS analysis is included in Table S1.

**Sanger sequencing and mutation validation**

Primers to amplify the 25 exons of GANAB (NM_198335.3), plus ~100bp of flanking IVS, were designed using MacVector 12.0.6 and 50ng of genomic DNA was used for PCR amplification (primers and PCR conditions available upon request). Sanger sequencing was performed at Beckman Coulter Genomics using standard approaches and variants identified with the
Mutation Surveyor software (Softgenetics) and designated on the 25 exon GANAB isoform and corresponding protein (NP_938149.2). Segregation analysis was performed where samples were available by sequencing the exonic fragment containing the mutation. Additionally, none of these variants were seen in the NHLBI Exome Sequence Project. Sanger sequencing detected amino acid changes were evaluated with the programs SIFT and Align GVGD and the atypical splicing change in M656 was evaluated with the BDGP Splice Site Prediction by Neural Network site. The origin of the GANAB families is: US, M263, M641, 290100, M656, M472; France, PK20016, PK20017; Macedonia, P1174; and Spain, P1073. One family came from the HALT PKD cohort, two from Genkyst, and the remainder from the Mayo PKD Center population.

**Generation of targeted GANAB mutated cell lines using CRISPR/Cas9**

Guide RNAs predicted to have the lowest off-targeting effect were cloned into pX330; SpCas9 and single guide RNA containing plasmid and verified by sequencing (see Table S2 for sequences). GANAB ex11-IVS12 was PCR amplified (primer sequences available on request) and the 550bp genomic product cloned into pCAG-EGxxFP<sup>52</sup> using BamHI and EcoRI restriction sites. Each gRNA was then co-transfected with p-CAG-EG-GANAB(11-IVS-12)-FP in RCTE cells and scored after 24hrs for EGFP positive cells. gRNA4 was selected as the most efficient cutter and used to generate cell lines. pX330-gRNA4 was transfected into WT RCTE cells by electroporation and the cells allowed to recover for 36hrs prior to splitting and re-seeding as single cell suspensions in a 96-well plate. Cells were grown for 10 days to establish single clone cell colonies, split two fold and re-seeded for screening. Screening was performed using genomic DNA extraction followed by amplification using GANAB ex11-IVS12 primers followed by the T7 mismatch assay. For this assay, PCR amplicons were denatured at 95°C for 2min and cooled gradually to 25°C at a rate of -2°C per second. The reaction mixture was then subjected to T7 endonuclease (T7E1, NEB) for 20min at 37°C and visualized in 2% agarose
gels. Clones were additionally screened using western blotting for GIIα and Sanger sequencing.

**Generating FLAG-GIIα constructs with missense variants**

C-terminal Myc-DDK tagged GIIα (isoform 3, NM_198335.3) was obtained from Origene. Missense mutations were introduced by site-directed mutagenesis using Q5 high-fidelity polymerase (NEB) (primer sequences are shown in Table S3).

**Western studies, glycosylation analysis and immunoprecipitation**

For crude membrane protein purification, cells were grown to confluence, washed with Dulbecco’s PBS (DPBS), scraped and reconstituted in LIS buffer (10mM Tris HCl pH 7.4, 2.5 mM MgCl₂, 1mM EDTA) plus protease inhibitors (Complete, Roche) and incubated on ice for 15min. Homogenized total membrane lysates were prepared by repeated passage through a 25.5 gauge needle and centrifugation at 4600 RPM for 5min. All procedures employed pre-chilled containers and were performed in the cold room to minimize protein loss to degradation. For IP, the crude membrane protein (75mg) pellet was solubilized in IP or high salt (500mM NaCl) IP buffer and samples pre-cleared with blank A/G agarose for 2hrs. Antibodies to PC1-CT and PC2 (YCE2) were added overnight and then incubated with 50ml of packed washed A/G Agarose (Thermo) for 2hrs. The agarose was washed 3x in IP buffer and once in ice-cold H₂O and the protein eluted in either LDS + TCEP or agarose was split into three equal parts (Untreated, EndoH and PNGaseF) and subjected to deglycosylation analyses. Purified membrane protein and IP eluates were deglycosylated with EndoH and PNGaseF according to the manufacturer's instructions (NEB). Twenty-five micrograms of input and 100% of the IP were loaded per SDS-PAGE lane.

**Surface glycoprotein labeling and immunoprecipitation**

Surface glycoprotein labeling of living cells was performed as previously described¹⁶. Monolayer cells in 10cm culture dishes were washed twice with ice-cold DPBS then oxidized at 4°C in 1mM
NaIO4 containing DPBS (pH 7) for 30min, quenched with ice-cold 1mM glycerol in DPBS for 5min, and washed twice with ice-cold DPBS. Oxime ligation was performed in the presence of 10mM Aniline (Sigma) and 100μM Alkoxylamine-PEG₂-Biotin (Thermo) in 1% FBS supplemented ice-cold DPBS (pH 7.5) buffer for 1hr. Biotinylated cells were then washed 3x in PBS and scraped. Reaction specificity was ensured using Streptavidin-488 (Alexa Fluor) staining of a small sample of cells and visualized using fluorescent microscopy. Scraped cells were collected by centrifugation, subjected to crude membrane protein purification and solubilized in IP Buffer (20mM HEPES pH 7.5, 137mM NaCl, 1% NP-40, 10% (w/v) Glycerol, 2mM EDTA, 2.5 mM MgCl₂) supplemented with protease inhibitors (Roche) for 15mins. Non-solubilized protein was removed by centrifugation and discarded. Neutravidin agarose was washed in IP buffer 3x and 50ml of packed agarose added to solubilized membrane protein and agitated at 4°C for 2hrs. Samples were washed three times in IP buffer and once in ice-cold H₂O. Protein was eluted in either LDS + TCEP or agarose subjected to deglycosylation analyses. Tris-Acetate gels were washed with ultrapure water and stained using ProteoSilver stain kit according to manufacturer’s instructions (Sigma) for silver staining.

**Transfection, confocal microscopy, immunofluorescence (IF) and surface PC1 labeling**

RCTE cells were split 1:2 the day before electroporation and transfected at ~80% confluency. Electroporation of RCTE cells was performed using the Biorad Gene Pulser with a square wave protocol: 110V, 25ms pulse and 0.2cm cuvettes (Biorad) in electroporation buffer (20mM HEPES, 135mM KCl, 2mM MgCl₂, 0.5% Ficoll 400, pH 7.6). TagGFP-PC2 and mCherry-PC1 used in this study were previously described.¹⁶ RCTE cells were grown on glass cover slips, washed once with DPBS, fixed in 3.5% paraformaldehyde (PF) for 30min, permeabilized with 0.1% Triton in DPBS (pH 7.5), washed again in PBS, and incubated in blocking buffer (10% normal goat serum (NGS), 1% BSA, 0.1% Tween in PBS pH 7.5) for 30mins. After three PBS washes, primary antibodies were added in IF buffer (1% BSA, PBS pH 7.5, 0.1% Tween) for
2hrs at room temperature or overnight at 4°C with gentle agitation. After three PBS washes, conjugated secondary antibody (AlexaFluor, Invitrogen) was added for 1hr. DAPI was added for 1 min to stain nuclei.

For surface labeling of mCherry-PC1, transfected RCTE cells were cooled at 4°C for 15min, washed once in ice-cold PBS and pre-chilled mCherry antibody (BioVision), and incubated in 0.5% BSA in PBS for 30mins at 4°C. Cells were then fixed in 3.5% paraformaldehyde (PF) and conjugated secondary antibody added for 30mins in IF buffer. Confocal microscopy was performed using a Zeiss Axiovert equipped with Apotome.

For pH-shift/SDS IF, the fixation/antigen retrieval method was performed to visualize endogenous PC2 in MEFs. Cells were grown to 100% confluency and serum starved for 48hrs, fixed in 3% PF (pH 7.5) for 15min, fixed in 4% (PF pH 11 in 100mM borate buffer) for 15min, and then permeabilized in 5% SDS for 5min, to partially denature the protein. Subsequently, PC2 antibody (H280) staining performed overnight at a 1:200 dilution at 4°C, as described above.

Antibodies
PC1 NT IgG1 7e1253 (WB 1/1000), PC1 CT Gt, EB08670, Everest Biotech (IP 1/250), PC2 Rb, H280, Santa Cruz (WB 1/5000, IF 1/200), PC2 IgG2a YCE2, Santa Cruz (WB 1/2000, IF 1/500), EGFR Rb, BD Transduction labs (WB 1/1000), Acetylated α-tubulin, IgG2b, Invitrogen (IF 1/5000), Anti-, mCherry Rb BioVision 5993-100 (Surface Labeling 1/1000), FLAG M2 IgG1 Sigma (IF 1/1000), α-Glucosidase II Abcam ab179805 (WB 1/2000).

RESULTS

Identification of GANAB as a gene mutated in ADPKD by whole exome sequencing
Following PKD1 and PKD2 mutation analysis for base pair and larger rearrangements, we identified 327 GUR families out of ~3600 screened. The origin of the GUR families was the HALT-PKD (64) ADPKD clinical trial, and the CRISP (16), and Genkyst (124) ADPKD observational studies. In addition, GUR families were included from screening ADPKD, and mild renal cystic disease families, including ones with PLD, at the Mayo PKD Center (123). While a firm clinical diagnosis of ADPKD was made in 247 GUR pedigrees, in 80 pedigrees the disease presentation was more atypical, with cystic kidney disease without kidney enlargement, although the vast majority exceeded the defined ultrasound or MRI criteria for ADPKD diagnosis. In the 7 remaining families, the disease presentation was more consistent with ADPLD, although all but one had some renal cysts. PRKCSH and SEC63 screening was also performed in these families before inclusion. Six multiplex ADPKD-like GUR families were screened by whole exome sequencing (WES) and standard screening methods employed to identify mutated, dominant genes (see Subjects and Methods), with detected genes/variants listed in Table S1. A missed PKD1 mutation was identified in one family (M560).

From this WES analysis, one candidate gene, GANAB, encoding the catalytic α subunit of glucosidase II (GIIα) appeared most promising since PRKCSH encodes the non-catalytic β subunit of this enzyme and mutations to this gene cause ADPLD. GANAB (Chr11q12.3) has two splice forms that in silico and RT-PCR analysis showed are approximately equally expressed in human kidney/liver (Figure S1): CDS: 2,988bp or 2,832bp; exons: 25 or 24 (inframe skipping of exon 6); genomic size: 21.9kb, AA: 966aa (~110kDa) or 944aa (~107kDa). We employed the larger splice form for mutation screening/designation and functional studies. ExAC exome data (60706 individuals) lists 5 loss of function (LoF) GANAB mutations compared to 49.7 expected (Probability of LoF intolerance [pLI]=1.0; see Subjects and Methods), a figure similar to PKD2 (7/37.6; pLI=1.0), and consistent with it being a dominant cause of disease.
The GANAB missense variant, c.1265G>T; p.Arg422Leu, was detected by WES in family M263 and found in the affected father and daughter but not the unaffected daughter (Figure 1A-C). In silico analysis, including conservation in a multi-sequence alignment (MSA) of orthologous proteins to yeast and related glucosidases showed and that this variant is highly predicted to be pathogenic (Figure 1D,E and legend). Both of the affected individuals had mild kidney and significant liver cystic disease (Figure 1F,G and Table 1).

**Identification of further ADPKD families with GANAB mutations**

Given that mutation to GANAB may explain unresolved ADPKD families, we analyzed our remaining GUR cohort of 321 families by Sanger sequencing of the coding region. From this analysis we identified eight additional families with GANAB mutations: three frameshifting, two splicing, one nonsense and two missense mutations (Table 1). Data from the Exome Aggregation Consortium (ExAC) showed that all the GANAB variants, except c.152_153delGA (reported once), have not been reported in the 60,706 unrelated individuals sequenced as part of various disease-specific and population genetic studies.

The GANAB frameshifting mutation, c.1914_1915delAG; p.Asp640Glnfs*77, was found in two families, M641 and 290100 (Figure 2A-E, Figures S2A,B, S3A, Table 1). In M641, two sisters had relatively mild PKD with variable liver cysts. The family history was unclear with the father dying at 75y with renal cell cancer but no reported cysts, with no information on the mother. Both sisters had ICA (see Figure 2 legend for details) and the father was reported to have a ruptured aneurysm. In family 290100, the father and son both had mild PKD, with multiple liver cysts in the father but not the son.

In family P1174, the GANAB missense variant, c.1214C>G; p.Thr405Arg, was found in three generations, including III-1 where renal cysts were detected incidentally in infancy (Figure 2F-H, Figures S2C, S3B, Table 1). The substituted residue is invariant in orthologs and conserved in
related proteins (Figure 2l,J). The GANAB splicing mutation, c.2690+2_+7del, was found in four affected family members in M656 (Figure 2K,L, Figures S2D, S3C,D, Table 1). All members had no to mild cystic liver disease and mild kidney disease, apart from II-3 who had multiple kidney cysts. Of note, the mother (without the GANAB mutation) had multiple cysts of unresolved etiology. PK20016 had the splicing mutation c.39-1G>C and PK20017 the nonsense mutation c.2176C>T; p.Arg726*, and both had only one known affected family member (Figure 3A-D, Figure S2E,F, Table 1). Both cases had multiple kidney cysts and a few liver cysts.

Identification of ADPLD-like families with GANAB mutations

In contrast to the described ADPKD cases, in families P1073 and M472 ADPLD was considered as a possible diagnosis, although a few renal cysts were present. P1073 had the missense mutation, c.2515C>T; p.Arg839Trp, which is at an invariant site in orthologs and segregates in three affected family members (Figure 3E-G, Figure S2G, Table 1). As indicated, there were very few renal cysts but multiple liver cysts, with the daughter, II-1, requiring a liver transplant at 43y. M472, II-1, with the GANAB frameshifting mutation c.152_153delGA; p.Arg51Lysfs*21 (Figure 3H,I, Figure S2H, Table 1), had a few small kidney cysts but severe PLD that required partial liver resections. A similar phenotype with less severe PLD was seen in II-2 (Figure S3E), although a sample was unavailable for mutation analysis.

Characterization of the effect of GANAB loss on PC1 and PC2 maturation/localization

From the genetic studies, mutation to GANAB was shown to be a cause of ADPKD/ADPLD, so we next explored the mechanism of pathogenesis by cellular analysis. CRISPR/Cas9 targeting of GANAB ex12 in human renal cortical tubular epithelial (RCTE) cells generated clones with biallelic frameshifting mutations (null; Clone C6) or a single in-frame deletion (heterozygous; E4; Figure S4A-D). Analysis of the PC complex immunocaptured with PC2 or PC1 CT antibodies in
GANAB<sup>−/−</sup> cells showed that the PC1 N-terminal, mature product (PC1-NTR) was absent (Figure 4A,B). In contrast, full length (GPS uncleaved) PC1, PC1-NTS and PC2 were elevated, indicating that GIIα plays a major role in PC1 maturation. We previously showed an interdependence of PC1 and PC2 for localization, including to cilia<sup>16</sup>, and so to assess localization of the polycystin complex PC2 was analyzed. Ciliary localization of PC2 was completely absent in GANAB<sup>−/−</sup> cells, although cilia formed normally (Figure 4C, Figure S4E)<sup>16</sup>; <sup>17</sup> Since affected individuals harbored just one GANAB mutation we assayed GANAB<sup>+/−</sup> cells and found a proportional, ~50%, depletion of PC1-NTR (Figure 4D,E). Analysis of the maturation of other membrane proteins (EGFR and E-cadherin) showed they were not, or only minorly, affected by loss of GIIα (Figure 4A). Further analysis of terminally glycosylated proteins in GANAB<sup>−/−</sup> cells did not suggest a global disruption of surface localized proteins (Figure S4F-H).

Functional analysis of GANAB mutations/variants

To determine the effect of GANAB loss on PC1 localization by immunofluorescence (IF) and to test the pathogenicity of detected GANAB/GIIα variants, wildtype and GANAB<sup>+/−</sup> cells were co-transfected with tagged PC1 and PC2 constructs (mCherry-PC1-V5 and GFP-PC2; Figure 5A,B)<sup>16</sup>. GIIα loss prevented efficient surface localization of tagged PC1, which was restored by co-expression of WT FLAG-GIIα (Figure 5A). Identified GIIα missense mutations (p.Thr405Arg, p.Arg422Leu and p.Arg839Trp), expressed as FLAG-GIIα constructs, failed to rescue PC1 surface localization in GANAB<sup>−/−</sup> cells (Figure 5A), whereas three other variants considered likely neutral (c.284A>G; p.Gln95Arg, c.760A>G; p.Thr254Ala and c.991C>T; p.Arg331Cys) restored surface localization (Figure S5).

DISCUSSION
The combination of the human genetic studies and cellular analysis of GANAB null cells show that mutations to GANAB cause ADPKD/ADPLD, that loss/reduction of GIIα · · · associated with maturation and localization defects of PC1 and PC2, and that the identified mutations cannot rescue the PC1 localization defect.

The renal phenotype associated with GANAB mutation is consistently mild without renal insufficiency and any kidney enlargement due to a few large cysts. The GANAB phenotype is more similar to PKD2 than PKD1, but apparently even milder. In one case there was more severe PKD (M656; II-3), and here an undetermined cystogenic influence from the mother may be significant. Applying imaging diagnostic criteria developed in PKD1 and PKD2 families may be unreliable in GANAB families even with a largely renal phenotype given the disease mildness and the variability within families. The significance of the vascular disease, noted in families M641, PK20017 and M472 is presently unclear. Only in M641 do the definitely affected sisters have ICA, with the vascular phenotypes in three other individuals in these families not proven to be GANAB mutation linked.

The liver disease is variable, ranging from no cysts to severe PLD requiring surgical intervention. The highly variable PLD phenotype is characteristic of ADPKD and ADPLD, with no data supporting allelic effects, although some evidence of familial clustering of severe PLD suggesting that genetic modifiers play a significant role. It is interesting that GANAB mutation was identified as the cause of the disease in two of the seven ADPLD-like pedigrees studied, suggesting that the mutation detection rate may be higher in ADPLD families. Although there may be ascertainment bias since ADPKD was the diagnosis in the vast majority of screened families, the overall phenotype appears to involve more renal disease than described in PRKCSH. The reason for this as they are subunits of the same protein is unclear, with further analysis of GANAB in ADPLD and PRKCSH in ADPKD populations, required. We consider that phenotypes consistent with mild ADPKD as well as ADPLD with a few renal cysts
can be caused by \textit{GANAB} mutation. Rather than considering ADPKD and ADPLD as strictly separate diseases, we suggest recording the full range of phenotypes associated with each gene where mutations are associated with ADPKD and/or ADPLD.

\textit{GANAB} mutation accounts for \textasciitilde3\% of GUR ADPKD families (\textasciitilde0.3\% total ADPKD), although since many GUR cases are likely missed \textit{PKD1/PKD2} mutations (see Introduction and\cite{24}), it is probably responsible for a much greater proportion of missing genetic causes of ADPKD. In addition, due to the mild phenotype it is likely underdiagnosed, and in particular, may be more common in families with mild PKD and significant PLD.

Defects in glycosylation and protein trafficking underlie a large number of human diseases\cite{60, 61}, but the interesting aspect here is the specificity of the phenotype associated with disruption of a step in a process important for many proteins. GII functions in the early cargo recruitment steps of the calnexin/calreticulin cycle, which facilitates the quality control and maturation of transmembrane glycoproteins\cite{35}. \textit{GANAB}\textsuperscript{−}\ cells and \textit{S. pombe} mutants are viable without growth defects\cite{62, 63}, and we demonstrate a lack of global, surface glycoprotein deficiencies in \textit{GANAB}\textsuperscript{−}\ cells, which suggests that endomannosidase activity and other chaperones and folding-assisting proteins can generally compensate for this loss, at least in non-stress conditions. The complexity due to protein size and extensive N-linked glycosylation may underlie the critical dependence of PC1 on GII and the calnexin/calreticulin cycle to achieve native folding. At this stage it is unclear if the enrichment of PLD associated with GII deficiency indicates that the liver is particularly vulnerable to reduction of this enzyme. The defect we observed in \textit{GANAB}\textsuperscript{−}\ cells is complete disruption of PC1 maturation, increasing ER accumulation of cleaved PC1 with only a marginal effect on GPS-cleavage, in contrast to that described for \textit{SEC63} deficiency\cite{16, 62, 64, 65}. In RCTE cells, \textit{GANAB} heterozygosity was associated with a \textasciitilde50\% reduction of PC1-NTR, a level predisposing to cyst development in association with stochastic, injury and/or somatic events\cite{13, 16, 66, 67}. However, further study is
required to fully understand quantitatively how PC1 maturation is influenced by GII dosage, studies that may lead to novel insights into a therapeutic role for cellular and molecular chaperones in ADPKD.
SUPPLEMENTAL DATA

Supplemental data includes one table and five figures.
ACKNOWLEDGEMENTS

Families and coordinators are thanked for their participation and efforts. The Exome Aggregation Consortium and groups that provided exome variant data, and Tatyana Masyuk for help with Family P1073, are also thanked. Other HALT PKD and CRISP investigators, including Drs. Grantham, Yu and Winklehofer (Kansas), Bae, Abebe, and Landsittel (Pittsburgh), Schrier and Brosnahan (Colorado), Perrone and Miskulin (Tufts), Braun (Cleveland Clinic), Steinman (Beth Israel), Mrug (UAB), Rahbari-Oskou (Emory), Bennett (Portland), Flessner (NIDDK), Moore (Charlotte), Czarnecki (Brigham and Women's Hospital) are also thanked. NIDDK grant DK058816, the Mayo PKD Translational Center (DK090728), an American Heart Association Post-doctoral fellowship (BP), the Mayo Clinic Nephrology Training grant (T32DK007013, VGG), an American Society of Nephrology (ASN) Foundation Kidney Research Fellowship (ECLG) and ASN Ben J Lipps Fellowship (KH), Mayo Graduate School (EKD), the Zell Family Foundation, and Robert M. and Billie Kelley Pirnie supported the study. The CRISP and HALT PKD studies were supported by NIDDK cooperative agreements (DK056943, DK056956, DK056957, DK056961 and DK062410, DK062408, DK062402, DK082230, DK062411, DK062401, respectively) and National Center for Research Resources General Clinical Research Centers (RR000039, RR000585, RR000054, RR000051, RR023940, RR001032) and National Center for Advancing Translational Sciences Clinical and Translational Science Awards (RR025008, TR000454, RR024150, TR00135, RR025752, TR001064, RR025780, TR001082, RR025758, TR001102, RR033179, TR000001). The Genkyst cohort was supported by National Plans for Clinical Research (PHRC inter-regional 2010 for the Genkyst study and PHRC inter-regional 2013 for the GeneQuest study), Groupement Inter-Régional de Recherche Clinique et d’Innovation (GIRGI grand-ouest) and the French Society of Nephrology.
CONFLICT OF INTEREST STATEMENT

No authors declare a conflict of interest in this study.
WEB RESOURCES

URLs for websites employed in this study

ADPKD Mutation Database (http://pkdb.mayo.edu)
Align GVGD (http://aqvgd.iarc.fr)
BDGP Splice Site Prediction by Neural Network (http://www.fruitfly.org/seq_tools/splice.html)
ExAC Browser (http://exac.broadinstitute.org)
National Center for Biotechnology Information (NCBI): Nucleotide
NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/)
Online Mendelian Inheritance in Man (http://www.omim.org)
SIFT (http://sift.jcvi.org)
REFERENCES


mutations and canonical Wnt signaling associated with hepatic cystogenesis. Proc Natl Acad Sci USA 111, 5343-5348.
Figure 1: WES analysis reveals a GANAB variant c.1265G>T; p.Arg422Leu in family M263 as the likely mutation

(A) Pedigree M263 showing that the two affected individuals (I-1 and II-1; black shaded) segregated the GANAB, c.1265G>T; p.Arg422Leu (p.R422L; ex12) missense mutation, but the unaffected daughter, II-2 (no cysts detected on ultrasound, 30y), did not. (B) GenomeBrowse (SVS, Golden Helix Inc.) view of the WES results from II-1 showing the GANAB variant
c.1265G>T (reverse strand), with details of the reads tabulated below. (C) Sanger sequencing confirmation in II-1 of heterozygous GANAB variant c.1265G>T; p.Arg422Leu (p.R422L), compared to wild type. (D) MSA of GIla orthologous proteins showing invariance of Arg422 from human to yeast. In silico analysis of the likely pathogenicity of GIla p.Arg422Leu (p.R422L) showed variant scores (SIFT=0.00; Align GVD=C65) characteristic of a highly likely pathogenic mutation. (E) MSA of related glucosidases, GANC (neutral alpha-glucosidase C) and GAA (lysosomal alpha-glucosidase) of various eukaryotic species and prokaryotic GH31 (glycosyl hydrolase family 31) showing invariant conservation of GIla Arg422. (F) CT scan with contrast of kidneys and liver of I-1 at 66y showing a few large kidney cysts (red arrows) and multiple scattered liver cysts (green arrows). (G) T2-weighted MR images from II-1 at 41y showing a few kidney (red arrows) and liver cysts (green arrows).
Figure 2: Characterization of GANAB mutations in four ADPKD families.

(A) Pedigree M641 with c.1914_1915delAG; p.Asp640Glnfs*77 (ex17) in two affected siblings. Both sisters had basilar tip aneurysms and II-2 also had two aneurysms detected on the left
middle cerebral artery. The affected status of the parents is unclear (gray shading); I-1 had renal cell carcinoma and a ruptured aneurysm but no reported PKD. (B) CT scan of kidneys and liver from II-2 showing multiple kidney and occasional liver cysts. (C) Pedigree 290100 showing c.1914_1915delAG in the father and son. MR images of II-1 (D) showing a few kidney but no hepatic cysts and I-1 (E) with a few kidney and scattered liver cysts. (F) Pedigree P1174 has c.1214C>G; p.Thr405Arg (p.T405R; ex11), in three affected individuals; III-2, with no cysts detected by ultrasound (US) at 5y, did not have the variant. (G) MRI of III-1 showing bilateral kidney cysts and US image of II-1 (H) with a single large renal cyst. (I) MSA of GANAB (GIIo) orthologs showing Thr405 invariant across species. In silico mutation analysis highly predicts p.Thr405Arg (p.T405R) as pathogenic (SIFT=0.00, Align GVD=G65). (J) MSA of GANAB-like proteins shows invariant conservation of this residue. (K) Pedigree M656 segregates c.2690+2_+7del (IVS20) in four affected members. Splicing predictions showed complete loss of the donor site. The mother (I-2), without the GANAB mutation, has ~5 kidney and ~30 liver cysts but no detected PKD1, PKD2, PRKCSH, or SEC63 mutation. (L) MR images of II-3 showing small hepatic and multiple renal cysts. Red and green arrows indicate kidney and liver cysts, respectively. Just representative cysts are highlighted where multiple cysts are present.
Figure 3: Characterization of GANAB variants in four families, including P1073 and M472 with an ADPLD diagnosis

(A) Pedigree PK20016 with the splicing mutation, c.39-1G>C (IVS1). The family history is unclear with samples unavailable, but one large renal cyst was reported in I-1. (B) CT-scan of II-1 showing bilateral kidney cysts and occasional hepatic cysts. (C) Pedigree PK20017 with c.2176C>T; p.Arg726* (p.R726*; ex18), in the proband II-1. Lack of DNA samples and clinical information precluded determining family history. II-2 died at 55y from a ruptured intracranial aneurysm, but his PKD status was unknown. (D) Ultrasound examination of II-1 shows several liver (left), and kidney cysts (right). (E) Pedigree P1073 segregates c.2515C>T; p.Arg839Trp (p.R839W; ex22), in three affected individuals. (F) CT scan of II-1 showing very few kidney cysts (left), but severe PLD (right). Gross images of the liver of this subject have been published68. (G) MSA of GANAB (GIIα) orthologs showing invariant conservation of Arg839 across species. In silico mutation analysis highly predicted p.Arg839Trp (p.R839W) as pathogenic (SIFT=0.00, Align GVDG=C65). (H) Pedigree M472 with c.152_153delGA; p.Arg51Lysfs*21 (p.R51fs; ex3) in II-1. (I) MR images from II-1 show a few renal cysts (left) but significant PLD, with this image subsequent to earlier resections (Table 1). No sample was available from II-2, but imaging showed also predominant PLD (Figure S3E). Parental DNA samples were unavailable and clinical information limited to determine family history, but I-1 was reported to have had a cerebral hemorrhage. Red and green arrows indicate kidney and liver cysts, respectively. Just representative cysts are highlighted where multiple cysts are present.
Figure 4. Gllα is required for PC1 ER-exit and maturation

(A) Deglycosylation analysis of wildtype (WT) and GANAB⁻/⁻ RCTE membrane protein treated with EndoH (+E), PNGaseF (+P) or untreated (Un). IP was used to enrich the PC1 complex with C-terminal PC1 (CT) or PC2 (YCE2) antibodies and immunodetected with the N-terminal PC1 (NT) antibody (7e12). Complete loss of the mature PC1 glycoform¹⁶ (NTR; red arrow) was observed in GANAB⁻/⁻ cells, with full length PC1 (FL) and PC1-NTS becoming more abundant. Mature E-cadherin and epidermal growth factor receptor (EGFR) were not or only marginally affected by GANAB loss, with the EndoH resistant protein (R, red arrow) persisting. No PC2 EndoH resistant form was noted, but the protein was upregulated in GANAB⁻/⁻ cells. Loss of WT Gllα was confirmed in GANAB⁻/⁻ cells using a C-terminal antibody. (B) Schematic representation of the observed PC1 banding pattern in WT and GANAB⁻/⁻ cells (A). (C) Confocal Z-stack rendering of primary cilia in confluent WT and GANAB⁻/⁻ cells detected for
acetylated α–tubulin (Ac.α–tub) and PC2, showing no cilia PC2 signal in GANAB<sup>−/−</sup> cells. Scale bar = 10 μm; DAPI stained nuclei; 100 ciliated cells analyzed (n=3) (D) Immunoblot of PC1 NT in WT and GANAB<sup>−/−</sup> cells shows a reduced level of PC1-NTR in GANAB<sup>−/−</sup> cells. Asterisk indicates a non-specific product<sup>16</sup>. (E) Quantification of PC1-NTR shows a reduction to ~50% (p<0.001, Students T test) in heterozygous and complete loss in homozygous, GANAB<sup>−/−</sup>, cells.
Figure 5: Surface localization of PC1 requires WT GIIα and is disrupted by GANAB missense mutations.

(A) WT and GANAB<sup>−/−</sup> cells co-transfected with WT tagged PC1 and PC2, mCherry-PC1 and TagGFP-PC2 (B), and examined for surface mCherry-PC1 labeling. Co-transfected cells were screened for live-cell surface PC1 signal and quantified as the percentage of surface positive PC1 relative to total co-transfected cells. Surface PC1 was detected on 55.0±6.8% of WT, but only 5.9±2.0% of GANAB<sup>−/−</sup> cells (P<0.0001), with the level rescued to 32.7±4.9% by co-transfection with the WT GANAB (FLAG-GIIα) plasmid. Co-transfection with the newly identified putative GANAB missense mutations cloned in FLAG-GIIα, p.Thr405Arg (p.T405R), p.Arg422Leu (p.R422L) and p.Arg839Trp (p.R839W), did not rescue PC1 surface localization (bottom three panels) (all P<0.0001 vs. WT rescue). Students T-test was performed to determine significance in at least 100 triple-transfected cells analyzed between three independent experiments. Scale bar=20µm.
Table 1. Clinical presentation of Autosomal Dominant Polycystic Kidney and Liver Disease in the 20 affected individuals from 9 GANAB mutant pedigrees

<table>
<thead>
<tr>
<th>Pedigree</th>
<th>GANAB Mutation</th>
<th>Subject</th>
<th>Sex</th>
<th>eGFR&lt;sup&gt;a&lt;/sup&gt;, age (y)</th>
<th>HBP&lt;sup&gt;b&lt;/sup&gt;, age (y)</th>
<th>Type&lt;sup&gt;d&lt;/sup&gt;</th>
<th>Age&lt;sup&gt;e&lt;/sup&gt;</th>
<th>Cysts</th>
<th>Vol&lt;sup&gt;f&lt;/sup&gt;</th>
<th>Fig.</th>
<th>Cysts</th>
<th>Vol&lt;sup&gt;g&lt;/sup&gt;</th>
<th>Fig.</th>
</tr>
</thead>
<tbody>
<tr>
<td>M263*</td>
<td>c.1265G&gt;T</td>
<td>I-1</td>
<td>M</td>
<td>78, 66</td>
<td>N, 67</td>
<td>CT</td>
<td>66</td>
<td>~10 bilateral, largest 11 cm</td>
<td>302&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1f</td>
<td>&gt;50 scattered, largest 6 cm</td>
<td>1226</td>
<td>1f</td>
</tr>
<tr>
<td></td>
<td></td>
<td>II-1</td>
<td>F</td>
<td>91, 42</td>
<td>N, 43</td>
<td>MRI</td>
<td>41</td>
<td>~10 bilateral, largest 3 cm</td>
<td>211</td>
<td>1g</td>
<td>&gt;20 scattered, largest 3 cm</td>
<td>835</td>
<td>1g</td>
</tr>
<tr>
<td>M641</td>
<td>c.1914_1915delAG</td>
<td>II-1</td>
<td>F</td>
<td>86, 51</td>
<td>Y, 40</td>
<td>CT</td>
<td>55</td>
<td>~15 bilateral, largest 10 cm</td>
<td>822&lt;sup&gt;a&lt;/sup&gt;</td>
<td>S3a</td>
<td>No liver cysts detected</td>
<td>150&lt;sup&gt;i&lt;/sup&gt;</td>
<td>S3a</td>
</tr>
<tr>
<td></td>
<td></td>
<td>II-2</td>
<td>F</td>
<td>104, 46</td>
<td>N, 50</td>
<td>CT</td>
<td>45</td>
<td>~10 bilateral, largest 6 cm</td>
<td>318&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2b</td>
<td>~20 scattered, largest 2 cm</td>
<td>764</td>
<td>2b</td>
</tr>
<tr>
<td>290100</td>
<td>c.1914_1915delAG</td>
<td>I-1</td>
<td>M</td>
<td>78, 65</td>
<td>N, 65</td>
<td>MRI</td>
<td>58</td>
<td>~8 bilateral, largest 2 cm</td>
<td>227</td>
<td>2e</td>
<td>&gt;30 scattered, largest 3 cm</td>
<td>1255</td>
<td>2e</td>
</tr>
<tr>
<td></td>
<td></td>
<td>II-1</td>
<td>M</td>
<td>87, 25</td>
<td>Y, 13</td>
<td>MRI</td>
<td>24</td>
<td>~12 bilateral, largest 2.5 cm</td>
<td>259</td>
<td>2d</td>
<td>None</td>
<td>832</td>
<td>2d</td>
</tr>
<tr>
<td>P1174</td>
<td>c.1214C&gt;G</td>
<td>I-1</td>
<td>M</td>
<td>N/A&lt;sup&gt;i&lt;/sup&gt;, N, 61</td>
<td>US</td>
<td>CT*</td>
<td>55</td>
<td>3 cysts in the left kidney</td>
<td>NE</td>
<td>S3b</td>
<td>1 cyst, 1.5 cm</td>
<td>NE</td>
<td>S3b</td>
</tr>
<tr>
<td></td>
<td></td>
<td>II-1</td>
<td>F</td>
<td>N/A&lt;sup&gt;i&lt;/sup&gt;, N, 35</td>
<td>US</td>
<td>29</td>
<td>2 cysts in the right kidney</td>
<td>NE</td>
<td>S2h</td>
<td>N/A</td>
<td>NE</td>
<td>S2h</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>III-1</td>
<td>M</td>
<td>122, 9</td>
<td>N, 9</td>
<td>MRI</td>
<td>9</td>
<td>~5 bilateral, largest 2 cm</td>
<td>116</td>
<td>2g</td>
<td>None</td>
<td>492</td>
<td>2g</td>
</tr>
<tr>
<td>M656</td>
<td>c.2690+2_+7del</td>
<td>I-1</td>
<td>M</td>
<td>N/A&lt;sup&gt;i&lt;/sup&gt;, Y, 55</td>
<td>CT*</td>
<td>67</td>
<td>Multiple small</td>
<td>NE</td>
<td>S3c</td>
<td>None</td>
<td>NE</td>
<td>S3c</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>II-1</td>
<td>M</td>
<td>84, 39</td>
<td>N, 39</td>
<td>US</td>
<td>44</td>
<td>Multiple reported</td>
<td>N/A</td>
<td>Multiple reported</td>
<td>N/A</td>
<td>Multiple reported</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>II-2</td>
<td>F</td>
<td>77, 50</td>
<td>N, 50</td>
<td>US</td>
<td>52</td>
<td>~5-10 bilateral, largest 2 cm</td>
<td>NE</td>
<td>S3d</td>
<td>&gt;20 scattered, largest 5 cm</td>
<td>NE</td>
<td>S3d</td>
</tr>
<tr>
<td></td>
<td></td>
<td>II-3</td>
<td>M</td>
<td>95, 49</td>
<td>Y, 35</td>
<td>MRI</td>
<td>43</td>
<td>&gt;30 scattered, largest 3 cm</td>
<td>SE</td>
<td>2l</td>
<td>&gt;20 scattered, largest 1 cm</td>
<td>NE</td>
<td>2l</td>
</tr>
<tr>
<td>PK20016</td>
<td>c.39-1G&gt;C</td>
<td>II-1</td>
<td>M</td>
<td>90, 53</td>
<td>Y, 45</td>
<td>CT*</td>
<td>52</td>
<td>~20 bilateral, largest 10 cm</td>
<td>665&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3b</td>
<td>~20 scattered, largest 2 cm</td>
<td>1449</td>
<td>3b</td>
</tr>
<tr>
<td>PK20017</td>
<td>c.2176C&gt;T</td>
<td>II-1</td>
<td>F</td>
<td>77, 78</td>
<td>Y, 53</td>
<td>US</td>
<td>78</td>
<td>~40 bilateral, largest 3 cm</td>
<td>NE</td>
<td>3d</td>
<td>~20 scattered, largest 1.5 cm</td>
<td>N/A</td>
<td>3d</td>
</tr>
<tr>
<td>P1073</td>
<td>c.2515C&gt;T</td>
<td>I-2</td>
<td>F</td>
<td>N/A&lt;sup&gt;i&lt;/sup&gt;, N/A</td>
<td>US</td>
<td>(78)</td>
<td>Unknown</td>
<td>N/A</td>
<td>Multiple reported</td>
<td>N/A</td>
<td>Multiple reported</td>
<td>N/A</td>
<td>Multiple reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>II-1</td>
<td>F</td>
<td>86, 50</td>
<td>N</td>
<td>CT*</td>
<td>43</td>
<td>~8 bilateral, largest 1 cm</td>
<td>196</td>
<td>3f</td>
<td>Severe PLD, Tx 43y</td>
<td>464&lt;sup&gt;i&lt;/sup&gt;</td>
<td>3f</td>
</tr>
<tr>
<td></td>
<td></td>
<td>II-2</td>
<td>M</td>
<td>N/A&lt;sup&gt;i&lt;/sup&gt;</td>
<td>N/A</td>
<td>US</td>
<td>(44)</td>
<td>Unknown</td>
<td>N/A</td>
<td>Multiple reported</td>
<td>N/A</td>
<td>Multiple reported</td>
<td></td>
</tr>
<tr>
<td>M472</td>
<td>c.152_153delGA</td>
<td>II-1</td>
<td>F</td>
<td>82, 58</td>
<td>N, 58</td>
<td>MRI</td>
<td>58</td>
<td>~20, largest 1 cm</td>
<td>223</td>
<td>3i</td>
<td>Severe PLD, resections 47y, 48y</td>
<td>1749&lt;sup&gt;i&lt;/sup&gt;</td>
<td>3i</td>
</tr>
<tr>
<td></td>
<td></td>
<td>II-2</td>
<td>F</td>
<td>N/A&lt;sup&gt;i&lt;/sup&gt;, N, 50</td>
<td>MRI</td>
<td>50</td>
<td>~16 bilateral, largest 6 cm</td>
<td>305&lt;sup&gt;a&lt;/sup&gt;</td>
<td>S3e</td>
<td>&gt;50 scattered, largest 5 cm</td>
<td>1249</td>
<td>S3e</td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**

- **a.** Mutation in this pedigree was first identified by whole exome sequencing.
- **b.** Based on last data available, expressed in ml/min/1.73m<sup>2</sup>, obtained using the CKD-EPI formula in adults<sup>10</sup> and the Schwarz formula in the pediatric case<sup>31</sup>. High blood pressure (HBP), yes (Y) or no (N) and age at HBP diagnosis or BP measurement. **c.** CT = computed tomography (CT) scan, CT* = contrast-enhanced CT scan, MRI = magnetic resonance imaging, US = ultrasound examination. **d.** Age at imaging examination. Values in parenthesis are present age if images not available. **e.** Kidney function was reported to be ‘within the normal range’. **f.** Sample unavailable and so GANAB mutation not confirmed. **g.** Kidney volume measurement or estimate (Vol). Values are measured height adjusted total kidney volume (htTKV) ml/m<sup>2</sup>; enlarged values, mean + 2SD of normal male and female htTKV<sup>46</sup>; not (NE) or slightly enlarged (SE), estimated when full images not available; images not available (N/A). **h.** Liver volume measurement or estimate (Vol). Values are measured height adjusted total liver volume (htTLV) ml/m<sup>2</sup>; enlarged values, mean + 2SD of normal male and female htTLV<sup>27</sup>; not enlarged (NE), estimates when full images not available; images not available (N/A). J = htTLV after resections.